Betta Pharmaceuticals (300558) Stock Overview
Researches and develops, manufactures, and markets medicines for the treatment of cancer in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
300558 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Betta Pharmaceuticals Co., Ltd. Competitors
Inner Mongolia Furui Medical Science
Jiangsu Nhwa Pharmaceutical
China Resources Double-Crane PharmaceuticalLtd
Chengdu Kanghong Pharmaceutical Group
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥45.86 |
| 52 Week High | CN¥79.80 |
| 52 Week Low | CN¥45.25 |
| Beta | 0.50 |
| 1 Month Change | -10.81% |
| 3 Month Change | -15.57% |
| 1 Year Change | -10.41% |
| 3 Year Change | -22.27% |
| 5 Year Change | -65.75% |
| Change since IPO | 81.26% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For Betta Pharmaceuticals Co., Ltd. (SZSE:300558) Suggests It's 41% Undervalued
Mar 13
Here's Why Betta Pharmaceuticals (SZSE:300558) Can Manage Its Debt Responsibly
Feb 25Betta Pharmaceuticals Co., Ltd. (SZSE:300558) Not Lagging Market On Growth Or Pricing
Feb 07Is Now The Time To Put Betta Pharmaceuticals (SZSE:300558) On Your Watchlist?
Dec 17Does Betta Pharmaceuticals (SZSE:300558) Have A Healthy Balance Sheet?
Nov 26We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings
Nov 04Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce
Sep 30Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 07Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares
Jul 30These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well
Jul 05Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem
Apr 26Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts
Apr 23What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You
Apr 16Shareholder Returns
| 300558 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.8% | -0.8% | 0.9% |
| 1Y | -10.4% | 16.1% | 28.3% |
Return vs Industry: 300558 underperformed the CN Pharmaceuticals industry which returned 18.4% over the past year.
Return vs Market: 300558 underperformed the CN Market which returned 30.5% over the past year.
Price Volatility
| 300558 volatility | |
|---|---|
| 300558 Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 9.7% |
| 10% least volatile stocks in CN Market | 3.1% |
Stable Share Price: 300558 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300558's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Lieming Ding | www.bettapharma.com |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat NSCLC, colorectal cancer, and other solid tumor indications. It also develops BPI-D0316, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutation; Vorolanib, a multi-target kinase inhibitor for various cancer treatment; EYP-1901, an investigational long-acting treatment for wet AMD, non-proliferative diabetic retinopathy, diabetic macular edema, and pmCNV; and MCLA-129, a bispecific antibody targeting both EGFR and c-Met.
Betta Pharmaceuticals Co., Ltd. Fundamentals Summary
| 300558 fundamental statistics | |
|---|---|
| Market cap | CN¥19.29b |
| Earnings (TTM) | CN¥303.28m |
| Revenue (TTM) | CN¥3.26b |
Is 300558 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300558 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.26b |
| Cost of Revenue | CN¥693.15m |
| Gross Profit | CN¥2.57b |
| Other Expenses | CN¥2.27b |
| Earnings | CN¥303.28m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 78.77% |
| Net Profit Margin | 9.29% |
| Debt/Equity Ratio | 40.3% |
How did 300558 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 07:38 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Betta Pharmaceuticals Co., Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Qiang | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |
| Ziyi Chen | Goldman Sachs |